Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.

Ma J, Liu L, Ling Y, Zheng J

Journal of biochemical and molecular toxicology26 Jul 2021Cited by 10 (Europe PMC)

PMID34309113DOI10.1002/jbt.22853PepBankPUB-34309113

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In DDP-resistant ovarian cancer cells, LTX‑315 lowered the IC50 of cisplatin.
In plain wordsIn drug-resistant ovarian cancer cells, LTX‑315 lowered the cisplatin concentration needed for half-maximal inhibition.
Peptide
LTX-315
Outcome
DecreaseDDP IC50
Study
n: not reported in source
DDP-resistant ovarian cancer cells
Outcome group
Tumor growth · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
DDP-resistant OC cell models were established, and LTX-315 treatment resulted in lower IC₅₀ of DDP.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911301
02LabIn vitro (cells)Efficacy outcome
In ovarian cancer cells, LTX‑315 reduced viability.
In plain wordsIn cells, LTX‑315 reduced ovarian cancer cell viability.
Peptide
LTX-315
Outcome
DecreaseCell viability
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Tumor growth · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911302
03LabIn vitro (cells)Efficacy outcome
In ovarian cancer cells, LTX‑315 reduced migration.
In plain wordsIn cells, LTX‑315 reduced ovarian cancer cell movement.
Peptide
LTX-315
Outcome
DecreaseCell migration
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Tumor growth · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911303
04LabIn vitro (cells)Efficacy outcome
In ovarian cancer cells, LTX‑315 reduced invasion.
In plain wordsIn cells, LTX‑315 reduced ovarian cancer cell invasion.
Peptide
LTX-315
Outcome
DecreaseCell invasion
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Tumor growth · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911304
05LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 reduced Bcl-2 expression.
In plain wordsIn cells, LTX‑315 reduced Bcl-2 expression.
Peptide
LTX-315
Outcome
DecreaseBcl-2 expression
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911305
06LabIn vitro (cells)Efficacy outcome
In ovarian cancer cells, LTX‑315 increased the apoptotic rate.
In plain wordsIn cells, LTX‑315 increased ovarian cancer cell apoptosis.
Peptide
LTX-315
Outcome
IncreaseApoptotic rate
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Tumor growth · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911306
07LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 increased cleaved caspase 3 expression.
In plain wordsIn cells, LTX‑315 increased cleaved caspase 3 expression.
Peptide
LTX-315
Outcome
IncreaseCleaved caspase 3 expression
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911307
08LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 increased cleaved PARP expression.
In plain wordsIn cells, LTX‑315 increased cleaved PARP expression.
Peptide
LTX-315
Outcome
IncreaseCleaved PARP expression
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911308
09LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 increased Bax expression.
In plain wordsIn cells, LTX‑315 increased Bax expression.
Peptide
LTX-315
Outcome
IncreaseBax expression
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911309
10LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 arrested the cell cycle.
In plain wordsIn cells, LTX‑315 arrested the ovarian cancer cell cycle.
Peptide
LTX-315
Outcome
Direction not reportedCell cycle arrest
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Tumor growth · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
In OC cells treated with LTX-315, the viability, migration, invasion and the expression of Bcl-2 of were repressed, but the apoptotic rate and the expression of cleaved caspase 3, cleaved PARP and Bax were increased, and the cell cycle was arrested.
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911310
11LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 increased Beclin-1 expression.
In plain wordsIn cells, LTX‑315 increased Beclin-1 expression.
Peptide
LTX-315
Outcome
IncreaseBeclin-1 expression
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911311
12LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 reduced p-Akt expression.
In plain wordsIn cells, LTX‑315 reduced p-Akt expression.
Peptide
LTX-315
Outcome
Decreasep-Akt expression
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911312
13LabIn vitro (cells)Mechanism
In ovarian cancer cells, LTX‑315 reduced p-mTOR expression.
In plain wordsIn cells, LTX‑315 reduced p-mTOR expression.
Peptide
LTX-315
Outcome
Decreasep-mTOR expression
Study
n: not reported in source
SKOV3, A2780, SKOV3/DDP and A2780/DDP ovarian cancer cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 and 20 µmol/LAs given in this study.
Source sentences
Summary
Moreover, LTX-315 promoted Beclin-1 expression level and inhibited p-Akt and p-mTOR expression levels
1 context sentence(design, population, supporting numbers)
Summary · context
SKOV3, A2780, SKOV3/DDP, and A2780/DDP cells (cisplatin [DDP]-resistant cells] were treated with different concentrations of LTX-315 (10 and 20 µmol/L), respectively.
Report a problemFND-3430911313

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.